| 摘要 |
Discloses an isolated polypeptide capable of eliciting an antigenspecific T-cell response to human cyclin A1 (CCNA1), said polypeptide being: a polypeptide of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10 or 9 amino acids of general formula I: N-X-C, [I] wherein: (a) X is an amino acid sequence that is selected from: CCNA1(120‐131) VDTGTLKSDLHF [SEQ ID NO:1], CCNA1(218‐226) AETLYLAVN [SEQ ID NO:2], CCNA1(227‐235) FLDRFLSCM [SEQ ID NO:3], CCNA1(253‐261) ASKYEEIYP [SEQ ID NO:4], CCNA1(118‐127) YEVDTGTLKS [SEQ ID NO:5], CCNA1(167‐175) YAEEIYQYL [SEQ ID NO:6], CCNA1(330‐339) LEADPFLKYL [SEQ ID NO:7], and CCNA1(341‐351) SLIAAAAFCLA [SEQ IN NO:8], (b) N is an amino terminus of the peptide and consists of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 amino acids that are independently selected from natural amino acids and non-natural amino acids, and (c) C is a carboxy terminus of the peptide and consists of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 amino acids that are independently selected from natural amino acids and non-natural amino acids. Also discloses the use of related antigen-pulsed antigen-presenting cells in the manufacture of a medicament for treating a condition characterised by CCNA1 overexpression in cells of a subject. |
